SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-21-160618
Filing Date
2021-05-13
Accepted
2021-05-13 16:50:21
Documents
49
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d128572d10q.htm 10-Q 840102
2 EX-31.1 d128572dex311.htm EX-31.1 10084
3 EX-31.2 d128572dex312.htm EX-31.2 10067
4 EX-32.1 d128572dex321.htm EX-32.1 5787
  Complete submission text file 0001193125-21-160618.txt   3019358

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cmpi-20210331.xml EX-101.INS 441121
6 XBRL TAXONOMY EXTENSION SCHEMA cmpi-20210331.xsd EX-101.SCH 29514
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpi-20210331_cal.xml EX-101.CAL 23746
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpi-20210331_def.xml EX-101.DEF 165483
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpi-20210331_lab.xml EX-101.LAB 234681
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpi-20210331_pre.xml EX-101.PRE 201960
Mailing Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 978-503-2124
Checkmate Pharmaceuticals, Inc. (Filer) CIK: 0001651431 (see all company filings)

IRS No.: 364813934 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39425 | Film No.: 21920431
SIC: 2836 Biological Products, (No Diagnostic Substances)